Characteristic of Drug Users Chronic Wound

The aim of this study is to describe demographic, clinical, etiological characteristic and evolution of drug addict's chronic wounds .

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Wound Drug Use Wounds and Injuries

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU De Nancy

Vandœuvre-lès-Nancy, 54500, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

all drug addict with chronic wound ( evolving at least since 1 month)

Exclusion criteria

use following medication inductor of cutaneous ulcer: hydroxycarbamide, gefitinib, cetuximab, sunitinib, sorafenib, pazopanib, gemcitabine, sirolimus, methotrexate, nicorandil .

Treatment and study plan

Primary outcomes

clinical venous insufficiency - presence of oedema

Time frame: at inclusion

presence of oedema

Secondary outcomes

clinical venous insufficiency - presence of varicose

Time frame: at inclusion

presence of varicose
clinical venous insufficiency - presence of white atrophy

Time frame: at inclusion

presence of white atrophy
clinical venous insufficiency - presence of varicose eczema

Time frame: at inclusion

presence of varicose eczema

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: TOXIPO

Important dates

Study start: 2018
Primary completion: 2019
Study completion: 2019
First posted: Jul 31, 2018
Registry last updated: Apr 12, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed